* patients with proven hypersensitivity or allergic reaction to quercetin or curcumin * patients with known chronic kidney disease with estimated creatinine clearance \< 50 ml/minute or need for dialysis * patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure * patients taking anticoagulant/antiplatelet drugs such as coumarine, heparine, aspirin, clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin. * patients with gallstone obstruction * hypothyroid suffering patients * patients with moderate or severe thrombocytopenia (platelet count \<100 ×10⁹/l); * pregnant patients

* patients with proven hypersensitivity or allergic reaction to quercetin or curcumin * patients with known chronic kidney disease with estimated creatinine clearance \< 50 ml/minute or need for dialysis * patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure * patients taking anticoagulant/antiplatelet drugs such as coumarine, heparine, aspirin, clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin. * patients with gallstone obstruction * hypothyroid suffering patients * patients with moderate or severe thrombocytopenia (platelet count \<100 ×10⁹/l); * pregnant patients

patients with proven hypersensitivity or allergic reaction to quercetin or curcumin patients with known chronic kidney disease with estimated creatinine clearance < 50 ml/minute or need for dialysis patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure patients taking anticoagulant/antiplatelet drugs such as coumarine, heparine, aspirin, clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin. patients with gallstone obstruction hypothyroid suffering patients patients with moderate or severe thrombocytopenia (platelet count <100 ×10⁹/l); pregnant patients

patients with proven hypersensitivity or allergic reaction to quercetin or curcumin patients with known chronic kidney disease with estimated creatinine clearance < 50 ml/minute or need for dialysis patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure patients taking anticoagulant/antiplatelet drugs such as coumarine, heparine, aspirin, clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin. patients with gallstone obstruction hypothyroid suffering patients patients with moderate or severe thrombocytopenia (platelet count <100 ×10⁹/l); pregnant patients

invasive mechanical ventilation needed. established limitation of the therapeutic effort inflammatory bowel disease (ibd: chron syndrome or ulcerative colitis), chronic diarrhea or malabsorption. previous neuromuscular disease. other disease with an estimated vital prognosis under 1 year. severe renal insufficiency (glomerular filtration rate <30 ml/min/1.73m2) medical records of cirrhosis, active chronic hepatitis or severe hepatic disease defined by got or gpt levels three times above the normal upper limit. patients with previous colchicine treatment for other diseases (mainly chronic prescriptions for familial mediterranean fever or gout). clearance period will not be required for patients treated with colchicine who stopped the treatment before the randomization. patients with history of allergic reaction or significant sensitivity to colchicine. treatment with immunosuppressive agents, corticoids or interleukine-1 antagonists for 6 months before inclusion. pregnant or breastfeeding female, confirmed by a positive result in the human chorionic gonadotropin (hcg) test. fertile woman, or post-menopausal during less than one year and non-surgically sterilized. women of fertile age may be included if using at least one contraceptive method and preferably two complementary contraceptive methods. use of other investigational drugs in the moment of inclusion, or during 30 days previous to inclusion.

invasive mechanical ventilation needed. established limitation of the therapeutic effort inflammatory bowel disease (ibd: chron syndrome or ulcerative colitis), chronic diarrhea or malabsorption. previous neuromuscular disease. other disease with an estimated vital prognosis under 1 year. severe renal insufficiency (glomerular filtration rate <30 ml/min/1.73m2) medical records of cirrhosis, active chronic hepatitis or severe hepatic disease defined by got or gpt levels three times above the normal upper limit. patients with previous colchicine treatment for other diseases (mainly chronic prescriptions for familial mediterranean fever or gout). clearance period will not be required for patients treated with colchicine who stopped the treatment before the randomization. patients with history of allergic reaction or significant sensitivity to colchicine. treatment with immunosuppressive agents, corticoids or interleukine-1 antagonists for 6 months before inclusion. pregnant or breastfeeding female, confirmed by a positive result in the human chorionic gonadotropin (hcg) test. fertile woman, or post-menopausal during less than one year and non-surgically sterilized. women of fertile age may be included if using at least one contraceptive method and preferably two complementary contraceptive methods. use of other investigational drugs in the moment of inclusion, or during 30 days previous to inclusion.

1. invasive mechanical ventilation needed. 2. established limitation of the therapeutic effort 3. inflammatory bowel disease (ibd: chron syndrome or ulcerative colitis), chronic diarrhea or malabsorption. 4. previous neuromuscular disease. 5. other disease with an estimated vital prognosis under 1 year. 6. severe renal insufficiency (glomerular filtration rate <30 ml/min/1.73m2) 7. medical records of cirrhosis, active chronic hepatitis or severe hepatic disease defined by got or gpt levels three times above the normal upper limit. 8. patients with previous colchicine treatment for other diseases (mainly chronic prescriptions for familial mediterranean fever or gout). clearance period will not be required for patients treated with colchicine who stopped the treatment before the randomization. 9. patients with history of allergic reaction or significant sensitivity to colchicine. 10. treatment with immunosuppressive agents, corticoids or interleukine-1 antagonists for 6 months before inclusion. 11. pregnant or breastfeeding female, confirmed by a positive result in the human chorionic gonadotropin (hcg) test. 12. fertile woman, or post-menopausal during less than one year and non-surgically sterilized. women of fertile age may be included if using at least one contraceptive method and preferably two complementary contraceptive methods. 13. use of other investigational drugs in the moment of inclusion, or during 30 days previous to inclusion.

1. invasive mechanical ventilation needed. 2. established limitation of the therapeutic effort 3. inflammatory bowel disease (ibd: chron syndrome or ulcerative colitis), chronic diarrhea or malabsorption. 4. previous neuromuscular disease. 5. other disease with an estimated vital prognosis under 1 year. 6. severe renal insufficiency (glomerular filtration rate <30 ml/min/1.73m2) 7. medical records of cirrhosis, active chronic hepatitis or severe hepatic disease defined by got or gpt levels three times above the normal upper limit. 8. patients with previous colchicine treatment for other diseases (mainly chronic prescriptions for familial mediterranean fever or gout). clearance period will not be required for patients treated with colchicine who stopped the treatment before the randomization. 9. patients with history of allergic reaction or significant sensitivity to colchicine. 10. treatment with immunosuppressive agents, corticoids or interleukine-1 antagonists for 6 months before inclusion. 11. pregnant or breastfeeding female, confirmed by a positive result in the human chorionic gonadotropin (hcg) test. 12. fertile woman, or post-menopausal during less than one year and non-surgically sterilized. women of fertile age may be included if using at least one contraceptive method and preferably two complementary contraceptive methods. 13. use of other investigational drugs in the moment of inclusion, or during 30 days previous to inclusion.